- Home
- AEYE vs AARD Comparison
AEYE vs AARD Comparison
Compare AEYE & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEYE | AARD |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 97.4M |
| IPO Year | 2011 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AEYE | AARD |
|---|---|---|
| Price | $12.32 | $1.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $17.33 | $7.50 |
| AVG Volume (30 Days) | 337.9K | ★ 1.2M |
| Earning Date | 10-26-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.56 | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,311,000.00 | N/A |
| Revenue This Year | $8.43 | N/A |
| Revenue Next Year | $10.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.52 | N/A |
| 52 Week Low | $5.31 | $0.93 |
| 52 Week High | $14.68 | $16.60 |
Technical Indicators
Market Signals| Indicator | AEYE | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 65.28 | 25.03 |
| Support Level | $6.03 | $0.93 |
| Resistance Level | $14.68 | $5.88 |
| Average True Range (ATR) | 1.20 | 0.35 |
| MACD | 0.30 | -0.05 |
| Stochastic Oscillator | 70.62 | 6.87 |
Price Performance
Historical ComparisonAbout AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.